Prima Biomed (PBMD) PT Lowered to $7 at Maxim Group, Buy Maintained as LAG-3 + Keytruda Moves to Higher Dose
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
December 29, 2016 4:06 AM ESTSYDNEY, AUSTRALIA -- (Marketwired) -- 12/29/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) clinical trial program for IMP321 in unresectable or metastatic melanoma patients. The Database Safety Monitoring Board (DSMB) confirmed that IMP321 is safe and well tolerated at the first dose level when used in combination with a PD-1 blocking antibody and dose escalation can continue as planned.
In this first-in-man combination Phase I study, IMP321 is combined with the PD-1 checkpoint inhibitor... More



